CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
Orca Biosystems, Inc.
Cellectar Biosciences, Inc.
Pfizer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Novartis
Juno Therapeutics, a Subsidiary of Celgene
Acerta Pharma BV
Oncternal Therapeutics, Inc
Astex Pharmaceuticals, Inc.
OriCell Therapeutics Co., Ltd.
Amgen
Kyowa Kirin Co., Ltd.
AO GENERIUM
Nordic Nanovector
Intellia Therapeutics
Celgene
Oncternal Therapeutics, Inc
Celularity Incorporated
Takeda
miRagen Therapeutics, Inc.
Merck Sharp & Dohme LLC
Takeda
miRagen Therapeutics, Inc.
Seagen Inc.
Seagen Inc.
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Ariad Pharmaceuticals
Seagen Inc.
AVEO Pharmaceuticals, Inc.
Probiomed S.A. de C.V.